Global Toxoplasmosis Treatment Drugs Market by Drug Class (Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others), by Indication (Chronic Toxoplasmosis Infection and Acute Toxoplasmosis Infection), by Route of Administration (Parenteral and Oral), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 3,310.1 Million in 2023 and is expected to exhibit a CAGR of 5.3% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing research and development activities are expected to drive the global toxoplasmosis treatment drugs market growth over the forecast period. For instance, on April 3, 2023, MDPI journal published that as fewer therapeutic options are available for treating toxoplasmosis, newer antiparasitic drugs that can block TgAPN2 M1 aminopeptidase are of significant value. Herein, researchers employed several computer-aided drug-design approaches with the objective of identifying drug molecules from the Asinex library with stable conformation and binding energy scores. By a structure-based virtual screening process, three molecules -LAS_52160953, LAS_51177972, and LAS_52506311, were identified. The compounds produced balanced interacting networks of hydrophilic and hydrophobic interactions, vital for holding the compounds at the docked cavity and stable binding conformation.
Global Toxoplasmosis Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.
COVID-19 had a negative impact on the global toxoplasmosis treatment drugs market due to increasing disruption of normal life of people due to nationwide lockdowns and increasing COVID infection. For instance, according to an article published by the National Center for Biotechnology Information on July 27, 2020, the prevalence of toxoplasmosis in human societies may serve as a proxy for hygiene, and it also exerts both direct and immune-mediated antiviral effects, hypothesizes a negative covariation between toxoplasmosis, and measures of the COVID-19 pandemic across countries. Research obtained aged-adjusted toxoplasmosis prevalence of pregnant women from the literature. Since the differences in the COVID-19 morbidity and mortality may depend on the different timing of the epidemics in each country, applied the date of first documented CoVID-19 in each country as a proxy of susceptibility, with a statistical control for population size effects.
Global Toxoplasmosis Treatment Drugs Market: Key Developments
Increasing research by key market players is expected to drive the market growth.
For instance, on March 11, 2022, Frontiers journal published an article explaining the rapid dose-dependent inhibition of T. gondii tachyzoites by Dihydroquinine (DHQ) compared to the standard drugs (SZ and PY) indicates that DHQ has high selective parasitical effects against tachyzoite proliferation. Remarkably, DHQ had an excellent selectivity index (SI) of 149- and 357-fold compared to 24- and 143-fold for PY and SZ, respectively, using fibroblast cells. In addition, DHQ disrupted T. gondii tachyzoite mitochondrial membrane potential and Adenosine Triphosphate (ATP) production and elicited high Reactive Oxygen Species (ROS) generation. Taking all these findings together, DHQ promises to be an effective and safe lead for the treatment of toxoplasmosis.
Browse 38 Market Data Tables and 48 Figures spread through 250 Pages and in-depth TOC on Global Toxoplasmosis Treatment Drugs Market, by Indication (Chronic Toxoplasmosis Infection and Acute Toxoplasmosis Infection), by Route of Administration (Parenteral and Oral), by Drug Class (Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/toxoplasmosis-treatment-drugs-market-4166
Key Takeaways of the Global Toxoplasmosis Treatment Drugs Market:
- The global toxoplasmosis treatment drugs market is expected to exhibit a CAGR of 5.3% during the forecast period due to increasing product launches. For instance, on September 15, 2020, Princeton University, based in the U.S. published an article explaining an international team of scientists found the new drug - designated JAG21 - to be highly effective against parasites in cell-based studies in the lab. JAG21 targets a molecule that is integral for the survival of the parasites that cause both toxoplasmosis and malaria.
- Among segmentation, the drug class segment is expected to be the dominant segment in the global toxoplasmosis treatment drugs market owing to the increasing treatments for toxoplasmosis. For instance, on December 20, 2022, WebMD LLC, a publishing company, stated currently recommended drugs in the treatment of toxoplasmosis act primarily against the tachyzoite form of T gondii; as a result, the parasite does not completely destroy the bradyzoite form. Pyrimethamine is the most effective agent and is included in most drug regimens. Leucovorin (ie, folinic acid) should be administered concomitantly to prevent bone marrow suppression. Unless circumstances preclude using more than 1 drug, a second drug (e.g., sulfadiazine, clindamycin) should be added. The efficacy of azithromycin, clarithromycin, atovaquone, dapsone, and cotrimoxazole is unclear; therefore, it should be used only as alternatives in combination with pyrimethamine. The most effective available therapeutic combination is pyrimethamine plus sulfadiazine or trisulfapyrimidines (e.g., a combination of sulfamerazine, sulfamethazine, and sulfapyrazine).
- Among region, North America is expected to be the dominant region in the global toxoplasmosis treatment drugs market, owing to the repurposed drugs for treatment of toxoplasmosis. On May 11, 2020, Springer Nature, a publishing company, published an article explaining NVP-AEW541 and GSK-J4 both compounds showed low toxicity to the host cell. Furthermore, researchers demonstrated that NVP-AEW541 inhibits tachyzoite invasion, while GSK-J4 HCl inhibits intracellular tachyzoite proliferation by halting cell cycle progression from G1 to S phase. These findings prompted to analyze the efficacy of the two compounds in vivo by using established mouse models of acute toxoplasmosis. In addition to prolonging the survival time of mice acutely infected with T. gondii, both compounds had a remarkable ability to reduce the parasite burden of tissues. Both NVP-AEW541 and GSK-J4 could be potentially repurposed as candidate drugs against T. gondii infection.
- The major players operating in the global toxoplasmosis treatment drugs market include Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd, Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.
